For these cases of metastatic disease or recurrence which cannot be managed with salvage local therapies, the preferred first-line regimen is either pembrolizumab monotherapy (for PD-L1 CPS ≥ 1) or pembrolizumab with platinum-doublet chemotherapy (any PD-L1) based on KEYNOTE-048 [28]. The gene discussed is CD274; the disease is metastatic neoplasm.